Despite advances in antibacterial therapy, the treatment of systemic mycoses in immunocompromised patients remains difficult because of a lack of effective antifungal agents with favorable pharmacokinetic and pharmacologic properties. Agents which have good oral bioavailability, a long half-life, high tissue penetration, minimal toxicity, and broad antifungal activity in immunocompromised patients are needed. Currently available drugs are either toxic and available only in intravenous form (amphotericin B) or are erratically absorbed and variably effective in immunocompromised patients (ketoconazole) (2) .
Sch 39304 (SCH) is a new N-substituted triazole antifungal compound that shows good pharmacokinetic properties in mice, rats, and humans (C. Lin, H. Kim Assay. Levels of SCH in plasma were determined by gas-liquid chromatography (GLC)-electron capture. Plasma (1 ml) was diluted with 0.5 ml of water and extracted with 5 ml of ethyl acetate by being mixed on a Vortex mixer for 1 min. After centrifugation, 4 ml of the organic layer was transferred to a clean tube and evaporated to dryness under nitrogen at 50°C. The residue was then dissolved in 1.5 ml of water and applied to a 1-ml disposable octadecyl extraction column (J. T. Baker Chemical Co., Phillipsburg, N.J.) which had been prewashed successively with 2 ml of methanol and 2 ml of water under a 5-to 10-mm Hg vacuum (Speed Mate-30; Applied Separations). The extraction column was then eluted with 2 ml of water followed by 1 ml of 10% methanol and 1.5 ml of methanol. The methanol fraction was collected and vortexed with 2.5 ml of hexane. After centrifugation, the methanol was evaporated to dryness under nitrogen. The Peak height ratio, retention times, and concentration were calculated by an HP-3357 Laboratory Automation System (Hewlett-Packard Co., Palo Alto, Calif.). Calculations of SCH concentrations were based on the ratio of the peak height of SCH to the peak height of the internal standard.
The calibration was done by an unweighted average of triplicate plasma standards (0.5 ,ug of SCH and 0.05 jig of internal standard per ml). The GLC method is specific for SCH, since the retention time of this drug was clearly different from those of several analogs (fluconazole, econazole, ketoconazole, miconazole, terconazole, and sulconazole). There was a good linear relationship between the peak height ratios and the concentrations. Regression analysis of the data revealed the following equation: y = 0.999x + 0.0024; r = 0.999. The sensitivity of the method was 0.025 ,ug/ml (coefficient of variation, 8.9%). Two concentrations (0.2 and 1.0 ,ug/ml) of SCH in plasma with six replications were prepared and analyzed in a single run. The mean observed concentrations were 0.205 ,ug/ml (coefficient of variation, 4.1%) and 0.993 p,g/ml (coefficient of variation, 3.2%), respectively, which indicated that the GLC method was accurate and reproducible.
Levels of SCH in tissue were determined as described above, using a 1:1 dilution with water of tissue homogenized in a blender. Tissues from untreated rabbits were used as controls. The sensitivity, linearity, and reproducibility of GLC analysis of SCH in tissues were similar to results with plasma.
Pharmacokinetic calculations. The areas under the plasma concentration-time curves (AUC) were calculated by using the linear trapezoidal rule up to the final measured concentration and then extrapolated to infinity (1). The terminal half-life in the postdistributive phase was determined by regression analysis with an unweighted least-linear-squares method. The volume of distribution at steady state (Vss) was determined by using the area under the moment curve (3). The pharmacokinetic parameters for each rabbit were individually determined. Differences in the means of each group were evaluated by Student's unpaired t test; a P value of <0.05 was considered significant.
RESULTS
Single-dose plasma pharmacokinetics. Composite graphs representing the average concentration in plasma over time for granulocytopenic and nongranulocytopenic rabbits are shown in Fig. 1 and 2 times of peak levels (Tmax) were not significantly different for granulocytopenic (Tmax = 3.6 + 0.5 h) and nongranulocytopenic (Tmax = 4.5 + 0.96 h) rabbits, with an overall mean Tmax of 4.0 ± 0.5 h. Similarly, the AUC, half-life, and V.,
were not significantly different between groups, since the overall means were 43.8 ± 3.4 ,ug * h/ml for AUC, 25 ± 1.4 h for half-life, and 3.8 ± 0.3 liters for Vss.
Tissue penetration. Table 1 shows the mean levels of SCH in tissue and the mean ratios of levels in tissue and plasma at steady state for multiple sites in granulocytopenic and nongranulocytopenic rabbits. Levels of SCH in all tissues examined equalled or exceeded simultaneous concentrations in plasma. The liver-to-plasma ratio was significantly (P < 0.05) greater than for other tissues, showing 8.5-to 15-fold-higher concentrations of drug in liver than in plasma. There was no significant difference (P >0.05) between the granulocytopenic and nongranulocytopenic rabbits in steady-state levels in plasma and in the mean ratios of concentrations in tissue and plasma.
DISCUSSION
This study demonstrates that SCH has favorable pharmacokinetic properties in both granulocytopenic and nongranulocytopenic rabbits. The drug was well absorbed, reaching a mean peak level within 4 h, but had a long half-life that led to detectable levels in plasma even 6 days after the relatively small dose of 2 mg/kg. This long half-life exceeds those of ketoconazole, miconazole, itraconazole, fluconazole, and flucytosine (4, 6) . This combination of good absorption and long half-life resulted in levels of SCH in plasma which exceeded the MICs for C. albicans (0.08 to 0.3 ,ug/ml) for as long as 48 h postdose (F. Meunier, C. Lambert, and P. Van der Auwera, 28th ICAAC, abstr. no. 162, 1988) .
To assess the ability of SCH to penetrate tissues, the means of the ratios of levels in tissue and plasma (Table 1) were calculated by determining the ratios of the levels in tissue and plasma for each individual rabbit in each group and then by calculating the mean of these six ratios. Thus, each value is not the ratio of the mean level in tissue over the mean level in plasma. This first method appears to be more representative of the true degree of tissue penetration, because even if a particular rabbit has a low level in plasma, its level in tissue may be many times higher, and thus its ratio, or relative degree of tissue penetration, would be high. Accordingly, tissue penetration at steady state was excellent, with drug levels that equalled or exceeded levels in plasma in multiple sites, including the central nervous system. The liver showed a nearly 10-fold-higher concentration and the spleen showed up to 3-fold-higher levels than were in plasma. These properties may be particularly favorable for treatment of hepatosplenic candidiasis and other mycoses which frequently infect the liver and spleen. Moreover, the ability of this drug to penetrate well into such tissues as the choroid, vitreous, bile, and kidney may permit effective therapy of fungal infections of these often inaccessible sites.
Neither granulocytopenia secondary to cytotoxic chemotherapy nor disseminated candidiasis inhibited the uptake of SCH into tissues. The trough levels in plasma after 14 daily doses were somewhat higher, though not significantly so, in the granulocytopenic rabbits (P > 0.05). Since granulocytopenic rabbits eat and drink less and are more docile than nongranulocytopenic ones, the trend toward higher levels after multidosing to steady state may be due to better compliance to drug feeding, diminished clearance or V, in these rabbits, or more complete absorption due to decreased binding of drug to gastrointestinal contents in the granulocytopenic rabbits. However, compliance in accepting SCH appeared to be similar for both groups. SCH may also bind to Candida lesions. Candida lesions in granulocytopenic rabbits are larger and more numerous than those in nongranulocytopenic rabbits and have a paucity of surrounding inflammatory cells. The absence of granulocytes around Candida lesions of granulocytopenic rabbits may permit better penetration of SCH into these foci. SCH may also be more slowly released from these lesions in granulocytopenic rabbits. Another possibility is that SCH may bind to circulating granulocytes. In granulocytopenic rabbits, more SCH may be present in the plasma than in the cellular fraction.
Clearly, no animal model can ever completely reproduce the complexity of a granulocytopenic patient. Granulocytopenic patients may differ somewhat from our granulocytopenic rabbits in that cytotoxic drugs other than cytosine arabinoside may cause greater mucosal damage, greater gut transit time, or other changes in these patients that may affect the absorption, distribution, and elimination of SCH. Nevertheless, the apparently favorable pharmacokinetic and pharmacological properties of SCH-good absorption, long half-life, excellent tissue penetration-make it a potentially useful antifungal drug.
